Artelo Biosciences, Inc. (ARTL) — Stock Valuation & Research

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with…

ARTL key statistics

Price$2.22
Market cap$7.74M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range2.05-179.19
Beta-0.07

Explore ARTL's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.